ADVERTISEMENT
Precision Medicine-Based Biomarkers for Traumatic Brain Injury
Precision Medicine-Based Biomarkers for Traumatic Brain Injury 
In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.
Precision Medicine-Based Biomarkers for Traumatic Brain Injury 
Precision Medicine-Based Biomarkers for Traumatic Brain Injury 

In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.

In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.

neuroscience, clinical trials, drug development

Illustration of light blue neurons with white amyloid plaques accumulating on their axons.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
Dan Robitzski | Sep 28, 2022 | 2 min read
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
A 3D rendering of a neuron
Independent FDA Advisory Panel Recommends Approving ALS Drug
Amanda Heidt | Sep 8, 2022 | 4 min read
The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.
A conceptual 3D illustration of motor neurons degrading
Canada Approves Experimental ALS Therapy
Andy Carstens | Jun 14, 2022 | 3 min read
The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.
3D illustration showing neurons inside the brain
Experimental Pill to Treat Parkinson’s Is Safe, Trial Finds
Andy Carstens | Jun 10, 2022 | 2 min read
Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.
Illustration of neurons in white with myelin in blue
Repurposed Drug Reverses Signs of Alzheimer’s in Mice, Human Cells
Jef Akst | Oct 12, 2021 | 2 min read
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
An artistic rendering of blue neurons against a white background
Participant’s Diagnosis Halts Gene Therapy Clinical Trial
Amanda Heidt | Aug 12, 2021 | 3 min read
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.
Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021 | 2 min read
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
New Drug Combo for ALS Slows Decline in Small Clinical Study
Jef Akst | Sep 3, 2020 | 3 min read
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
Interactive: Biomarkers in Blood Provide a Window into the Brain
Shawna Williams | Dec 1, 2019 | 1 min read
A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.
The Hunt for a Blood Test for Alzheimer’s Disease
Shawna Williams | Dec 1, 2019 | 10 min read
Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.
Drug Approval Could Boost Research on Marijuana Treatment for Autism
Jessica Wright | Aug 17, 2018 | 4 min read
Epidiolex, a cannabis-derived medicine for epilepsy, will prompt federal regulatory changes that could crack open access to study the plant.
New Support for Experimental Alzheimer’s Drug
Jef Akst | Nov 2, 2016 | 2 min read
Merck’s verubecestat, which is currently being tested in two Phase 3 studies, is safe, according to newly published Phase 1 data.
Alzheimer's Drugs Harmful?
Bob Grant | Feb 20, 2012 | 1 min read
The researcher who helped develop an Alzheimer's treatment now in clinical trials warns that the compound may actually impair memory.
ADVERTISEMENT